亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

医学 易普利姆玛 无容量 舒尼替尼 肾细胞癌 内科学 肿瘤科 癌 第一行 随机对照试验 临床试验 癌症 免疫疗法
作者
Robert J. Motzer,Brian I. Rini,David F. McDermott,Osvaldo Arén Frontera,Hans J. Hammers,Michael A. Carducci,Pamela Salman,Bernard Escudier,Benoit Beuselinck,Asim Amin,Camillo Porta,Saby George,Victoria Neiman,Sergio Bracarda,Scott S. Tykodi,Philippe Barthélémy,Raya Leibowitz‐Amit,Elizabeth R. Plimack,Sjoukje F. Oosting,Bruce G. Redman
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:20 (10): 1370-1385 被引量:760
标识
DOI:10.1016/s1470-2045(19)30413-9
摘要

Summary

Background

In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile. In this study, we aimed to assess efficacy and safety after extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sunitinib in this setting.

Methods

In the phase 3, randomised, controlled CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by International Metastatic Renal Cell Carcinoma Database Consortium risk status into favourable-risk, intermediate-risk, and poor-risk subgroups and randomly assigned (1:1) to open-label nivolumab (3 mg/kg intravenously) plus ipilimumab (1 mg/kg intravenously) every 3 weeks for four doses, followed by nivolumab (3 mg/kg intravenously) every 2 weeks; or sunitinib (50 mg orally) once daily for 4 weeks (6-week cycle). Randomisation was done through an interactive voice response system, with a block size of four and stratified by risk status and geographical region. The co-primary endpoints for the trial were overall survival, progression-free survival per independent radiology review committee (IRRC), and objective responses per IRRC in intermediate-risk or poor-risk patients. Secondary endpoints were overall survival, progression-free survival per IRRC, and objective responses per IRRC in the intention-to-treat population, and adverse events in all treated patients. In this Article, we report overall survival, investigator-assessed progression-free survival, investigator-assessed objective response, characterisation of response, and safety after extended follow-up. Efficacy outcomes were assessed in all randomly assigned patients; safety was assessed in all treated patients. This study is registered with ClinicalTrials.gov, number NCT02231749, and is ongoing but now closed to recruitment.

Findings

Between Oct 16, 2014, and Feb 23, 2016, of 1390 patients screened, 1096 (79%) eligible patients were randomly assigned to nivolumab plus ipilimumab or sunitinib (550 vs 546 in the intention-to-treat population; 425 vs 422 intermediate-risk or poor-risk patients, and 125 vs 124 favourable-risk patients). With extended follow-up (median follow-up 32·4 months [IQR 13·4–36·3]), in intermediate-risk or poor-risk patients, results for the three co-primary efficacy endpoints showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival (median not reached [95% CI 35·6–not estimable] vs 26·6 months [22·1–33·4]; hazard ratio [HR] 0·66 [95% CI 0·54–0·80], p<0·0001), progression-free survival (median 8·2 months [95% CI 6·9–10·0] vs 8·3 months [7·0–8·8]; HR 0·77 [95% CI 0·65–0·90], p=0·0014), and the proportion of patients achieving an objective response (178 [42%] of 425 vs 124 [29%] of 422; p=0·0001). Similarly, in intention-to-treat patients, nivolumab and ipilimumab showed improved efficacy compared with sunitinib in terms of overall survival (median not reached [95% CI not estimable] vs 37·9 months [32·2–not estimable]; HR 0·71 [95% CI 0·59–0·86], p=0·0003), progression-free survival (median 9·7 months [95% CI 8·1–11·1] vs 9·7 months [8·3–11·1]; HR 0·85 [95% CI 0·73–0·98], p=0·027), and the proportion of patients achieving an objective response (227 [41%] of 550 vs 186 [34%] of 546 p=0·015). In all treated patients, the most common grade 3–4 treatment-related adverse events in the nivolumab and ipilimumab group were increased lipase (57 [10%] of 547), increased amylase (31 [6%]), and increased alanine aminotransferase (28 [5%]), whereas in the sunitinib group they were hypertension (90 [17%] of 535), fatigue (51 [10%]), and palmar-plantar erythrodysaesthesia (49 [9%]). Eight deaths in the nivolumab plus ipilimumab group and four deaths in the sunitinib group were reported as treatment-related.

Interpretation

The results suggest that the superior efficacy of nivolumab plus ipilimumab over sunitinib was maintained in intermediate-risk or poor-risk and intention-to-treat patients with extended follow-up, and show the long-term benefits of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma across all risk categories.

Funding

Bristol-Myers Squibb and ONO Pharmaceutical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ubless607发布了新的文献求助50
2秒前
李健的应助被萧雨墨采纳,获得10
2秒前
初初初啊发布了新的文献求助10
3秒前
cjy完成签到 ,获得积分10
5秒前
6秒前
cccc完成签到,获得积分10
7秒前
温良完成签到 ,获得积分10
9秒前
10秒前
11秒前
初初初啊发布了新的文献求助10
12秒前
科研通AI6.4的应助被香果采纳,获得10
12秒前
突突完成签到 ,获得积分10
13秒前
14秒前
15秒前
15秒前
sue发布了新的文献求助10
17秒前
18秒前
18秒前
无语的幻露完成签到,获得积分10
18秒前
初初初啊发布了新的文献求助10
20秒前
萧雨墨发布了新的文献求助10
21秒前
21秒前
千早爱音完成签到 ,获得积分10
21秒前
DTS发布了新的文献求助10
22秒前
23秒前
23秒前
抚琴祛魅完成签到 ,获得积分10
24秒前
29秒前
何在完成签到,获得积分10
30秒前
Lucas的应助被DTS采纳,获得10
31秒前
33秒前
Ziezer完成签到,获得积分10
34秒前
初初初啊发布了新的文献求助10
34秒前
生性不爱说话完成签到,获得积分10
36秒前
DTS完成签到,获得积分10
38秒前
可爱多婷婷子完成签到 ,获得积分10
38秒前
单身的曲奇完成签到,获得积分10
39秒前
霸气的远望完成签到 ,获得积分10
42秒前
42秒前
Nole的应助被pursuit采纳,获得30
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190060
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851884
捐赠科研通 7788155
什么是DOI,文献DOI怎么找? 3436233
关于科研通互助平台的介绍 2559935
邀请新用户注册赠送积分活动 2482792